Elekta (OTCMKTS:EKTAY) vs. NeurAxis (NASDAQ:NRXS) Financial Review

NeurAxis (NASDAQ:NRXS) and Elekta (OTCMKTS:EKTAY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Risk & Volatility

NeurAxis has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Elekta has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 41.3% of Elekta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares NeurAxis and Elekta”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32 million	16.84	-$14.63 million	($0.78)	-9.14
Elekta	$1.78 billion	1.22	-$55.38 million	($0.12)	-49.33

NeurAxis has higher earnings, but lower revenue than Elekta. Elekta is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for NeurAxis and Elekta, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	1	1	0	2.50
Elekta	0	1	0	0	2.00

NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 82.33%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities analysts plainly believe NeurAxis is more favorable than Elekta.

Profitability

This table compares NeurAxis and Elekta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Elekta	-2.38%	13.47%	3.84%

Summary

NeurAxis beats Elekta on 8 of the 14 factors compared between the two stocks.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.